Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Pricing At The High Court: Justices Friendlier To Enforcement From States Than 340B Entities

Executive Summary

U.S. Supreme Court justices’ skepticism over the right of 340B entities to sue pharmaceutical companies for overcharges does not appear to extend to states’ ability to challenge drug prices reported under Medicaid.
Advertisement

Related Content

Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices
Supreme Court Agrees With Drug Firms That 340B Providers Cannot Sue Over Prices
Problems With 340B? GAO Is Now Gathering Information From Drug Manufacturers
Problems With 340B? GAO Is Now Gathering Information From Drug Manufacturers
Supreme Court Is Wary Of Healthcare Provider Suits Alleging Overpricing By Pharma
Supreme Court Is Wary Of Healthcare Provider Suits Alleging Overpricing By Pharma
340B Price Setting Policy Should Precede Dispute, Penalty Actions, BIO Urges

Topics

Advertisement
UsernamePublicRestriction

Register

PS053084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel